Yesterday, Nov. 24, 2015, 106 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $189.51 to $48,391,506.50.

Highlighted Stocks Traded by Insiders:

Chubb (CB) - FREE Research Report

Brundage Maureen A, who is EVP & General Counsel at Chubb, sold 13,000 shares at $131.27 on Nov. 24, 2015. Following this transaction, the EVP & General Counsel owned 13,060 shares meaning that the stake was reduced by 49.88% with the 13,000-share transaction.

The shares most recently traded at $130.63, down $0.64, or 0.49% since the insider transaction. Historical insider transactions for Chubb go as follows:

  • 4-Week # shares sold: 3,500
  • 12-Week # shares sold: 3,500
  • 24-Week # shares sold: 20,664

The average volume for Chubb has been 1.3 million shares per day over the past 30 days. Chubb has a market cap of $29.8 billion and is part of the financial sector and insurance industry. Shares are up 26.45% year-to-date as of the close of trading on Tuesday.

The Chubb Corporation, through its subsidiaries, provides property and casualty insurance to businesses and individuals. The stock currently has a dividend yield of 1.74%. The company has a P/E ratio of 15.1. Currently, there are 5 analysts who rate Chubb a buy, no analysts rate it a sell, and 8 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CB - FREE

TheStreet Quant Ratings

rates Chubb as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, increase in net income and attractive valuation levels. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full

Chubb Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Jazz Pharmaceuticals (JAZZ) - FREE Research Report

Mulligan Seamus, who is Director at Jazz Pharmaceuticals, sold 27,968 shares at $145.86 on Nov. 24, 2015. Following this transaction, the Director owned 1.1 million shares meaning that the stake was reduced by 2.41% with the 27,968-share transaction.

The shares most recently traded at $149.69, up $3.83, or 2.56% since the insider transaction. Historical insider transactions for Jazz Pharmaceuticals go as follows:

  • 4-Week # shares sold: 5,421
  • 12-Week # shares sold: 12,621
  • 24-Week # shares sold: 26,521

The average volume for Jazz Pharmaceuticals has been 773,700 shares per day over the past 30 days. Jazz Pharmaceuticals has a market cap of $9.1 billion and is part of the health care sector and drugs industry. Shares are down 10.21% year-to-date as of the close of trading on Tuesday.

Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a P/E ratio of 28.3. Currently, there are 10 analysts who rate Jazz Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on JAZZ - FREE

TheStreet Quant Ratings

rates Jazz Pharmaceuticals as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, compelling growth in net income, good cash flow from operations, expanding profit margins and impressive record of earnings per share growth. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full

Jazz Pharmaceuticals Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Independence Realty (IRT) - FREE Research Report

Dunkelberg William C, who is Director at Independence Realty, bought 500 shares at $7.55 on Nov. 24, 2015. Following this transaction, the Director owned 9,500 shares meaning that the stake was boosted by 5.56% with the 500-share transaction.

The shares most recently traded at $7.62, up $0.07, or 0.86% since the insider transaction. Historical insider transactions for Independence Realty go as follows:

  • 4-Week # shares bought: 2,000
  • 12-Week # shares bought: 2,000
  • 24-Week # shares bought: 2,000

The average volume for Independence Realty has been 204,500 shares per day over the past 30 days. Independence Realty has a market cap of $355.9 million and is part of the financial sector and real estate industry. Shares are down 18.9% year-to-date as of the close of trading on Tuesday.

Independence Realty Trust, Inc is an equity real estate investment trust launched by RAIT Financial Trust. It is managed by Independence Realty Advisors, LLC. The fund invests in the real estate markets of the United States. It makes investments in apartment properties to create its portfolio. The stock currently has a dividend yield of 9.52%. The company has a P/E ratio of 10.2. Currently, there are 3 analysts who rate Independence Realty a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on IRT - FREE

TheStreet Quant Ratings

rates Independence Realty as a

sell

. The area that we feel has been the company's primary weakness has been its generally disappointing historical performance in the stock itself. Get the full

Independence Realty Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.